In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014–2015

Diagnostic Microbiology and Infectious Disease

Volumn 91, Issue 1, 2018, Pages 55-62

  Zhanel, George G ^a   Baxter, Melanie R ^a   Adam, Heather J ^a   Sutcliffe, Joyce ^b   Karlowsky, James A ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Tetraphase Pharmaceuticals Inc   (United States)

Author keywords

CANWARD; Eravacycline; Gram negative; Gram positive; In vitro; Surveillance

Indexed keywords

CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; ERAVACYCLINE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN; 7-FLUORO-9-PYRROLIDINOACETAMIDO-6-DEMETHYL-6-DEOXYTETRACYCLINE; ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BROTH DILUTION; CANADA; CONTROLLED STUDY; DRUG POTENCY; ENTEROBACTERIACEAE; ENTEROCOCCUS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRAM POSITIVE COCCI; HOSPITAL LABORATORY; HOSPITAL PATIENT; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STAPHYLOCOCCUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS; DRUG EFFECT; ENTEROBACTERIACEAE INFECTION; EPIDEMIOLOGICAL MONITORING; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; CANADA; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; EPIDEMIOLOGICAL MONITORING; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LABORATORIES, HOSPITAL; MICROBIAL SENSITIVITY TESTS; TETRACYCLINES;

EID: 85044729723     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2017.12.013     Document Type: Article

References (26)

1. Abdallah, M., Olafisoye, O., Cortes, C., Urban, Landman, D., Quale, J., Activity of eravacycline against Enterobactericeae and Acinetobacter baumannii including multidrug-resistant isolates from New York City. Antimicrob Agents Chemother 59:3 (2015), 1802–1805.
2. Clinical and Laboratory Standards Institute (CLSI), Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically—tenth edition: approved standard M07-A10. 2015, CLSI, Wayne, PA.
3. Clinical and Laboratory Standards Institute (CLSI), Performance standards for antimicrobial susceptibility testing. Twenty-sixth informational supplement. Document M100-S26. 2016, CLSI, Wayne, PA.
4. Denisuik, A.J., Lagace-Wiens, P.R.S., Pitout, J.D., Mulvey, M.R., Simner, P.J., Tailor, F., et al. Molecular epidemiology of extended-spectrum β-lactamase AmpC β-lactamase and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007–2011. J Antimicrob Chemother 68:Suppl. 1 (2013), i57–65.
5. Falagas, M.E., Mavroudis, A.D., Vardakas, K.Z., The antibiotic pipeline for multi-drug resistant gram-negative bacteria: what can we expect?. Expert Rev Anti Infect Ther 14:8 (2016), 747–763.
6. Fyfe, C., LeBlanc, G., Close, B., Nordmann, P., Dumas, J., Grossman, T.H., Eravacycline is active against bacterial isolates expressing the polymyxin resistance gene mcr-1. Antimicrob Agents Chemother 60:11 (2016), 6989–6990.
7. Golding, G.R., Campbell, J.L., Spreitzer, D.J., Veyhl, J., Surynicz, K., Simor, A., et al. A preliminary guideline for the assignment of methicillin-resistant Staphylococcus aureus to a Canadian pulsed-field gel electrophoresis epidemic type using spa typing. Can J Infect Dis Med Microbiol 19 (2008), 273–281.
8. Grossman, T.H., Starosta, A.L., Fyfe, C., O'Brien, W., Rothstein, D.M., Mikolajka, A., et al. Target and resistance based mechanistic studies with TP-434 a novel fluorocycline antibiotic. Antimicrob Agents Chemother 56:5 (2012), 2559–2564.
9. Grossman, T.H., Murphy, T.M., Slee, A.M., Lofland, D., Sutcliffe, J.A., Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob Agents Chemother 59:5 (2015), 2567–2571.
10. Grossman, T.H., O'Brien, W., Kerstein, K.O., Sutcliffe, J.A., Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli. Antimicrob Agents Chemother 59:4 (2015), 2446–2449.
11. Johnson, J.R., Porter, S.B., Jonston, B.D., Thuras, P., Activity of eravacycline against Escherichia coli clinical isolates collected from US veterans in 2011 I relation to coresistance phenotype and sequence type 131 genotype. Antimicrob Agents Chemother 60:3 (2016), 1888–1891.
12. Livermore, D.M., Mushtaq, S., Warner, M., Woodford, N., In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother 60:6 (2016), 3840–3844.
13. Monogue, M.L., Thabit, A.K., Hamada, Y., Nicolau, D.P., Antibacterial efficacy of eravacycline in vivo against gram-positive and gram-negative organisms. Antimicrob Agents Chemother 60:8 (2016), 5001–5005.
14. Nichol, K.A., Adam, H.J., Roscoe, D.L., Golding, G.R., Lagace-Wiens, P.R.S., Hoban, D.J., et al. Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada. J Antimicrob Chemother 68:Suppl. 1 (2013), i47–55.
15. Simner, P.J., Adam, H.J., Baxter, M., McCracken, M., Golding, G.R., Karlowsky, J.A., et al. Epidemiology of vancomycin-resistant enterococci in Canadian hospitals (CANWARD study, 2007–2013). Antimicrob Agents Chemother 59:7 (2015), 4315–4317.
16. Solomkin, J.S., Ramesh, M.K., Cesnauskas, G., Novikovs, N., Stefanova, P., Sutcliffe, J.A., et al. Phase 2 randomized double blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adults community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother 58:4 (2014), 1847–1854.
17. Solomkin, J., Evans, D., Slepavicius, A., Lee, P., Marsh, A., Tsai, L., et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg, 2016, 10.1001/jamasurg.2016.4237 [Epub ahead of print].
18. Sutcliffe, J.A., O'Brien, W., Fyfe, C., Grossman, T.H., Antibacterial activity of eravacycline (TP-434) a novel fluorocycline against hospital and community pathogens. Antimicrob Agents Chemother 59:11 (2013), 5548–5558.
19. Thaden, J.T., Pogue, J.M., Kaye, K.S., Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence, 2016, 1–14.
20. Tsai L, Zervos M, Miller L, et al. Intravenous eravacycline compared to intravenous levofloxacin for the treatment of complicated urinary tract infection (cUTI): subgroup analysis of a randomized double-blind phase 3 trial (IGNITE2). Abstract. MO-265. ASM microbe; June 16–20, 2016, Boston, MA.
21. Xiao, X.Y., Hunt, D.K., Zhou, J., Clark, R.B., Dunwoody, N., Fyfe, C., et al. Fluorocyclines 1,7 fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent broad spectrum antibacterial agent. J Med Chem 55:2 (2012), 597–605.
22. Wyeth Pharmaceuticals Inc, Tygacil (tigecycline)—tigecycline injection, powder, lyophilized, for solution. Prescribing information. 2016, Wyeth Pharmaceuticals Inc., Philadelphia, PA.
23. Zhang, Y., Lin, X., Bush, K., In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline. J Antibiot (Tokyo) 69:8 (2016), 600–604.
24. Zhanel, G.G., Karlowsky, J.A., Rubinstein, E., Hoban, D.J., Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther 4:1 (2006), 9–25.
25. Zhanel, G.G., Adam, H.J., Baxter, M.R., Fuller, J., Nichol, K., Denisuik, A., et al. Antimicrobial susceptibility of 22,746 pathogens from Canadian hospitals; results of the CANWARD 2007-2011 study. J Antimicrob Chemother 68:Suppl. 1 (2013), 7–22.
26. Zhanel, G.G., Cheung, D., Adam, H., Zelenitsky, S., Golden, A., Schweizer, F., et al. Review of eravacycline a novel fluorocycline antibacterial agent. Drugs 76:5 (2016), 567–588.